"If the pharmaceutical industry had developed a single drug capable of reducing cancer mortality by 25%, autoimmune disorders by 39%, and COVID-19 infection rates by 74%, it would be heralded as a miracle drug."
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The 2025 immunization guidelines marked a shift from quadrivalent to trivalent influenza vaccines, introduced new RSV timing protocols, and revised multiple vaccination schedules, including meningococcal B dosing for ages 16-23 years.